|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date15 Sep 1999 |
HCKJ-HN01滴眼液单次/多次给药在健康受试者中的安全性、耐受性和药代动力学特征的I期临床试验
[Translation] Phase I clinical trial of safety, tolerability and pharmacokinetic characteristics of single/multiple administration of HCKJ-HN01 eye drops in healthy subjects
1) 观察HCKJ-HN01滴眼液在健康受试者中单次/多次给药的安全性; 2) 确定HCKJ-HN01滴眼液在健康受试者中的最大耐受剂量(MTD); 3) 探索HCKJ-HN01滴眼液在健康受试者中单次/多次给药的药代动力学特征。
[Translation] 1) To observe the safety of single/multiple administration of HCKJ-HN01 eye drops in healthy subjects; 2) To determine the maximum tolerated dose (MTD) of HCKJ-HN01 eye drops in healthy subjects; 3) To explore the pharmacokinetic characteristics of single/multiple administration of HCKJ-HN01 eye drops in healthy subjects.
100 Clinical Results associated with Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd.